Irland - engelsk - HPRA (Health Products Regulatory Authority)

laboratoire aguettant - atropine sulfate monohydrate - solution for injection in pre-filled syringe - 0.1 milligram(s)/millilitre - belladonna alkaloids, tertiary amines; atropine - belladonna alkaloids, tertiary amines - atropine sulfate aguettant 0.1 mg/ml, solution for injection in pre-filled syringe is indicated in adults and in paediatric population from birth, but with a body weight superior to 3 kg - as a pre-anaesthetic medication to prevent vagal reactions associated with tracheal intubation and surgical manipulation, - to limit the muscarinic effects of neostigmine, when given postsurgically to counteract non-depolarising muscle relaxants - treatment of hemodynamically compromising bradycardia and/ or atrioventricular block due to excessive vagal tone in emergency situation - cardiopulmonary resuscitation: to treat symptomatic bradycardia and av block - as antidote following overdosage or poisoning with acetylcholinesterase-inhibitors e.g. anticholinesterases, organophosphorus, carbamates and muscarinic mushrooms

USA - engelsk - NLM (National Library of Medicine)

alcon laboratories, inc. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate 10 mg in 1 ml - isopto® atropine 1% is indicated for: atropine sulfate ophthalmic solution should not be used in anyone who has demonstrated a previous hypersensitivity or known allergic reaction to any ingredient of the formulation because it may recur. risk summary there are no adequate and well-controlled studies with isopto® atropine 1% administration in pregnant women to inform a drug-associated risk. adequate animal development and reproduction studies have not been conducted with atropine sulfate. in humans, 1% atropine sulfate is systemically bioavailable following topical ocular administration [see clinical pharmacology (12.3)] . isopto® atropine 1% should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. there is no information to inform risk regarding the presence of atropine in human milk following ocular administration of isopto® atropine 1% to the mother. the effects on breastfed infants and the effects on milk production are also unknown.  the developmental a

USA - engelsk - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - 1. in the treatment of parkinsonism. rigidity and tremor relieved by the apparently selective depressant action. 2. in the gastrointestinal tract to relieve pylorospasm, hypertonicity of the small intestine and the hypermotility of the colon. 3. to relieve hypertonicity of the uterine muscle. 4. to relax the spasm of biliary and uretered colic and bronchial spasm. 5. to diminish the tone of the detrusor muscle of the urinary bladder in the treatment of urinary tract disorders. 6. to control the crying and laughing episodes in patients with brain lesions. 7. in cases of closed head injuries which cause acetylcholine to be released or to be present in cerebrospinal fluid which in turn causes abnormal eeg patterns, stupor and neurological signs. 8. in the management of peptic ulcer. 9. in anesthesia to control excessive salivation and bronchial secretions. 10. to control rhinorrhea of acute rhinitis or hay fever. 11. as an antidote for pilocarpine, physostigmine,

USA - engelsk - NLM (National Library of Medicine)

a-s medication solutions - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate injection, usp, is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. none. animal reproduction studies have not been conducted with atropine. it also is not known whether atropine can cause fetal harm when given to a pregnant woman or can affect reproduction capacity. trace amounts of atropine was found in breast milk. the clinical impact of this is not known. recommendations for use in pediatric patients are not based on clinical trials. an evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disea

Malta - engelsk - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - atropine sulfate - solution for injection in a pre-filled syringe - atropine sulfate 0.1 mg/ml - drugs for functional gastrointestinal disorders

Malta - engelsk - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - atropine sulfate - solution for injection in a pre-filled syringe - atropine sulfate 0.1 mg/ml - drugs for functional gastrointestinal disorders

Malta - engelsk - Medicines Authority

pinewood laboratories limited ballymacarbry, clonmel, co. tipperary, ireland - atropine sulfate - tablet - atropine sulfate 600 µg - drugs for functional gastrointestinal disorders

Israel - engelsk - Ministry of Health

teva israel ltd - atropine sulfate - solution for injection - atropine sulfate 20 mg / 10 ml - atropine - atropine - preanesthetic medication to decrease excessive salivation and secretions of the respiratory tract. treatment of sinus bradycardia, particularly if complicated by hypotension. antidote in poisoning by organophosphorus.

USA - engelsk - NLM (National Library of Medicine)

sebela pharmaceuticals inc. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), difenoxin hydrochloride (unii: vqz63k01iw) (difenoxin - unii:3zz5bj9f2q) - atropine sulfate 0.025 mg - motofen® is indicated as adjunctive therapy in the management of acute nonspecific diarrhea and acute exacerbations of chronic functional diarrhea. motofen® is contraindicated in patients with diarrhea associated with organisms that penetrate the intestinal mucosa (toxigenic e. coli, salmonella species, shigella ) and pseudomembranous colitis associated with broad spectrum antibiotics. antiperistaltic agents should not be used in the conditions because they may prolong and/or worsen diarrhea. motofen® is contraindicated in children under 2 years of age because of the decreased margin of safety of drugs in this class in younger age groups. motofen® is contraindicated in patients with a known hypersensitivity to difenoxin, atropine, or any of the inactive ingredients, and in patients who are jaundiced. motofen® tablets are a schedule iv controlled substance. addiction to (dependence on) difenoxin hydrochloride is theoretically possible at high dosage. therefore, the recommended dosage should not be e

USA - engelsk - NLM (National Library of Medicine)

vedco, inc - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - ndc 50989-075-12 atropine sulfate injection 1/120 grain sterile multiple dose vial net contents: 100 ml vedco keep out of reach of children for animal use only caution:   federal law restricts this drug to use by or on the order of a licensed veterinarian. for intravenous, intramuscular, or subcutaneous use composition : each ml contains: atropine sulfate  ............................  0.54 mg sodium chloride .................................  9 mg benzyl alcohol (preservative)...............  1.5% water for injection  ...............................  q.s. ph adjusted with sulfuric acid when necessary.